Coherent receives ISO 13485 certification for Goettingen facility
Coherent Inc. has recently expanded its ISO 13485 certification in Europe to include the Excimer laser design and manufacturing facility located in Goettingen, Germany.
Santa Clara, Calif., Sept. 11, 2009 Coherent Inc. (Santa Clara, CA) (Nasdaq: COHR) has recently expanded its ISO 13485 certification in Europe to include the Excimer laser design and manufacturing facility located in Goettingen, Germany. ISO 13485 is an international standard that defines the requirements of comprehensive quality management systems for the design, development, production, customer service and assembly of medical devices. ISO 13485 also specifies protocols for adherence to customer requirements and product improvement within the European regulatory framework for medical devices.
“Achieving ISO 13485 certification benefits all customers who integrate Coherent’s excimer laser products into their surgical systems for eye correction,” notes Heiner Felder, Quality Manager for Medical Products. “The Goettingen certification provides Coherent’s medical customer with expanded capabilities and supplements the existing ISO 13485 certification of the Munich facility. We have now successfully integrated and synchronized all our quality systems for excimer lasers within Coherent.”
Founded in 1966, Coherent, Inc. is a Russell 2000 Index company and a world leader in providing laser-based solutions to the commercial and scientific research markets. Please direct any questions to Heiner Felder, Quality Manager for Medical Products at +49 89 5892746 10. For more information about Coherent, including product and financial updates, visit our website at:
www.coherent.com/excimer
Contact details
Petra Wallenta, PR Manager Europe
+49 89 5892746 25
petra.wallenta@coherent.com
Heiner Felder
+49 89 5892746 10
heiner.felder@coherent.com
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Evaluating the clinical performance of ZEISS AT ELANA and the new ’ELISA’* approach
August 2nd 2025In this insightful analysis, Dr. Joong Hun Kim presents real-world clinical outcomes with bilateral implantation of ZEISS AT ELANA 841P. Dr. Kim recommends AT ELANA® 841P as an excellent option for patients undergoing cataract surgery as its fully trifocal optical design translates into a full range of vision. He also introduces the so-called ‘ELISA’ approach for patients requiring astigmatic correction in one eye only, combining AT ELANA 841P and ZEISS AT LISA tri toric 939MP. Early objective and subjective clinical data from this novel approach reveal promising visual outcomes and high patient satisfaction
